Evidence map›Paper›PMID 39247951›Full record

ArticleAnnals of surgery2024

The First Case of Intra-portal Islet Implantation During Liver Machine Perfusion Allowing Simultaneous Islet-liver Transplantation in A Human: A New and Safe Treatment for End-stage Liver Disease Combined With Diabetes Mellitus.

Qiang Zhao, Jiahao Li, Zepeng Lin, Yunhua Tang, Daopeng Yang, Meiting Qin, Xue Ma, Haibin Ji, Honghui Chen, Tielong Wang and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of surgery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Qiang ZhaoOrgan Transplant Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Jiahao LiOrgan Transplant Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Zepeng LinOrgan Transplant Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Yunhua TangOrgan Transplant Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Daopeng YangOrgan Transplant Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Meiting QinOrgan Transplant Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Xue MaOrgan Transplant Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Haibin JiOrgan Transplant Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Honghui ChenOrgan Transplant Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Tielong WangOrgan Transplant Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Maogen ChenOrgan Transplant Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Weiqiang JuOrgan Transplant Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Dongping WangOrgan Transplant Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Zhiyong GuoOrgan Transplant Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Xiaofeng ZhuOrgan Transplant Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Jia DanOrgan Transplant Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Anbin HuOrgan Transplant Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Xiaoshun HeOrgan Transplant Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveEvaluating the safety and efficacy of implanting a liver with islet grafts into patients with end-stage liver disease and diabetes mellitus (DM).

backgroundDM and end-stage liver diseases are significant health concern worldwide, often coexisting and mutually influencing each other. Addressing both diseases simultaneously is paramount.

methodsWe utilized the islet transplantation combined ischemia-free liver transplantation (ITIFLT) technique to treat a patient with hepatocellular carcinoma (HCC) and type 2 diabetes mellitus (T2DM). The liver was procured and preserved using the ischemia-free liver transplantation (IFLT) technique, and during normothermic machine perfusion (NMP), isolated and purified islet grafts were transplanted into the liver through the portal vein. Finally, the liver, incorporating with the transplant islet grafts, was implanted into the recipient without interruption of blood supply.

resultsThe patient received both liver and islet graft from the same donor. The patient achieved insulin-independence by post-transplant day (PTD) 9, and both liver and islet function remained robust. The patient was discharged on PTD 18 and experienced no surgical or transplantation-related complications during the follow-up period. Furthermore, islet grafts presence was observed in liver biopsies after islet transplantation.

conclusionsThis landmark case marks the inaugural application of ITIFLT in humans, signifying its potential as a promising treatment modality for end-stage liver disease with DM.

Identifiers

PMID39247951
PMCPMC11723485

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.